Pilot study on recurrent aphthous stomatitis (RAS): a randomized placebo-controlled trial for the comparative therapeutic effects of systemic prednisone and systemic montelukast in subjects unresponsive to topical therapy

Femiano, F; Buonaiuto, C; Gombos, F; Lanza, Alessandro; Cirillo, Nicola

doi:10.1016/j.tripleo.2009.10.024

Cited by 62 publications

(54 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Any part of the oral cavity may be involved, 81,82 but the tongue and floor of the mouth are usually spared. 83 Longstanding disease leads to fissuring with a "snail track appearance," in addition to cobblestoning. Symptoms of burning and pain may be present.…”

Section: Pyostomatitis Vegetansmentioning

confidence: 99%

“…85 Histopathologically, PSV is characterized by epithelial acanthosis and superficial ulceration with intraepithelial and/or subepithelial microabscesses. 83,84 PSV usually parallels the activity of the underlying bowel disease, 84 and there are reports of mucosal lesions after regression of IBD flare or after surgical treatment of IBD.…”

Section: Pyostomatitis Vegetansmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous Manifestations in Patients With Inflammatory Bowel Diseases

Marzano

Borghi

Stadnicki

et al. 2014

Inflammatory Bowel Diseases

120

View full text Add to dashboard Cite

The skin is one of the most common extraintestinal organ system affected in patients with inflammatory bowel disease (IBD), including both Crohn's disease and ulcerative colitis. The skin manifestations associated with IBD are polymorphic and can be classified into 4 categories according to their pathophysiology: (1) specific, (2) reactive, (3) associated, and (4) induced by IBD treatment. Cutaneous manifestations are regarded as specific if they share with IBD the same granulomatous histopathological pattern: perianal or metastatic Crohn's disease (commonly presenting with abscesses, fistulas or hidradenitis suppurativa-like features) is the prototype of this setting. Reactive cutaneous manifestations are different from IBD in the histopathology but have close physiopathological links: pyoderma gangrenosum, a neutrophil-mediated autoinflammatory skin disease typically manifesting as painful ulcers, is the paradigm of this group. Among the cutaneous diseases associated with IBD, the most commonly seen are erythema nodosum, a form of panniculitis most commonly involving bilateral pretibial areas, and psoriasis, a T helper 1/T helper 17-mediated erythematous squamous inflammatory disease. Finally, the number of cutaneous adverse reactions because of IBD therapies is progressively increasing. The most frequent drug-induced cutaneous manifestations are psoriasis-like, eczema-like, and lichenoid eruptions, as well as cutaneous lupus erythematosus for biologics, and nonmelanoma skin cancer, mainly basal cell and squamous cell carcinomas for thiopurines.

show abstract

Section: Pyostomatitis Vegetansmentioning

confidence: 99%

Section: Pyostomatitis Vegetansmentioning

confidence: 99%

Cutaneous Manifestations in Patients With Inflammatory Bowel Diseases

Marzano

Borghi

Stadnicki

et al. 2014

Inflammatory Bowel Diseases

120

View full text Add to dashboard Cite

show abstract

“…[7][8][9] In particular, anti-inflammatory and immunomodulatory agents such as clofazimine, thalidomide, pentoxifylline, colchicine, levamisole, azathioprine, amlexanox, and steroids have been administered with varying clinical benefits. [10][11][12][13][14][15][16][17][18][19][20] Cyclosporine A (CsA) is a potent immunosuppressive agent that interferes with both B-and T-cell activation. It is widely used to prevent organ transplant rejection and in the treatment of various systemic and local immune diseases.…”

Section: Introductionmentioning

confidence: 99%

A new approach to the treatment of recurrent aphthous stomatitis with bioadhesive gels containing cyclosporine A solid lipid nanoparticles: in vivo/in vitro examinations

Karavana¹,

Gökçe²,

Rençber³

et al. 2012

IJN

View full text Add to dashboard Cite

Aim:To develop a suitable buccal bioadhesive gel formulation containing cyclosporine A solid lipid nanoparticles (CsA SLNs) for the treatment of recurrent aphthous stomatitis. Methods: The suitability of the prepared formulations for buccal application was assessed by means of rheological studies, textural profile analysis, and ex vivo drug-release studies. Plastic flows, typical gel-like spectra, and suitable mechanical properties were obtained from prepared formulations. The retention time was explored in in vivo distribution studies and the effect of the gel containing CsA SLNs on the healing of oral mucosal ulceration was investigated in an animal model. In vivo distribution studies are a very important indicator of the retention time of formulations at the application site. Results: Distribution studies showed that 64.76% ± 8.35% of the formulation coded "F8+SLN" remained on the buccal mucosa 6 hours after application. For the second part of the in vivo experiments, 36 rabbits were separated into three groups: the first group was treated with the gel formulation without the active agent; the second group with the gel formulation containing CsA SLNs; and the third group, used as the control group, received no treatment. Wound healing was established by scoring of the rate of wound healing on Days 3, 6, 9, and 12. Histological observations were made on the same days as the scoring studies. The bioadhesive gel formulation that included CsA SLNs increased the rate of mucosal repair significantly. Conclusion: This study has shown that the bioadhesive gel formulation containing CsA SLNs reported here is a promising candidate for the topical treatment of recurrent aphthous stomatitis.

show abstract

“…11 With 20 patients in each arm, patients were treated with either a prednisone taper, montelukast or placebo for a course of 2 months and followed for a further 2 months following the end of treatment. Prednisone provided faster resolution and greater pain relief (by day 2-3) than montelukast, but montelukast did provide more benefit than placebo (day 3-4 vs. day [4][5].…”

Section: Montelukastmentioning

confidence: 99%